Acasti Pharma Inc. (ACST) shares are trading at lower $0.20 and the avg recommendation for the stock is Moderate Buy.
To add more color to this target, the company’s high over the last year is $3.08 and the low is $0.18. Over the last 52 weeks, ACST is down -90.75% while the S&P 500 is up 13.97%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, ACST reported a profit of $0.55 million. Acasti Pharma Inc. also saw revenues increase to $4.12 million. In addition, ACST has free cash flow of -$4.34 million as of 06-2020. The company’s EBITDA came in at -$3.57 million which compares well with its peers.
Find out when ACST reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ACST has a short ratio of 0.05 and outstanding shares of 96.89M.
ACST has seen increased volume after this news and investors are putting their support behind the value proposition. Traders will also note the company’s earnings per share came in at -0.24. Acasti Pharma Inc. ACST also noted assets of $20.14 million at the end of the last quarter. Investors should also keep an eye on sector updates as ACST has historically followed its peers on positive news.
All told, Acasti Pharma Inc. ACST has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ACST represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Acasti Pharma Inc. ACST is now commanding a market cap of 19.37M and a float of 93.52M. ACST is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ACST stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in ACST, either long or short, and we have not been compensated for this article.